Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Transl Med ; 11(2): 123, 2023 Jan 31.
Article in English | MEDLINE | ID: mdl-36819540

ABSTRACT

Background: To explore the key genes, biological functions, and pathways of empagliflozin in the treatment of type 2 diabetes mellitus (T2DM) through network pharmacology. Methods: The TCMSP (a traditional Chinese medicine system pharmacology database and analysis platform) was used to screen empagliflozin's active components and targets. The target genes of T2DM were screened according to the GeneCards and OMIM databases, and a Venn diagram was constructed to obtain the target for T2DM treatment. Cytoscape 3.7.2 software was adopted to construct the drug-component-target-disease network. Functional annotation of Gene Ontology (GO) and enrichment analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were performed using R software. Results: Target genes with a probability >0 were selected, among which Compound 012, Compound 060, Compound 093, Compound 111, and Compound 119 Swiss Target Prediction suggested that no similar active substances or predictable target genes were found. A "compound-target gene-disease" network was constructed, in which SLC5A2, SLC5A1, SLC5A4, SLC5A11, ADK, and ADORA2A were the core genes of T2DM. The key factors of the GO summary map included chemical reaction, membrane organelle, protein binding, and so on. The KEGG pathway summary map included the AMPK pathway, insulin resistance, the MAPK pathway, longevity-related pathway regulation, and so on. The top 10 pathways were endocrine resistance, the NF-κB signaling pathway, the HIF-1 signaling pathway, apoptosis, cell senescence, the Ras signaling pathway, the MAPK signaling pathway, the FoxO signaling pathway, the P13K-Akt signaling pathway, and the p53 signaling pathway. The binding of active compounds to key proteins was verified based on the Swiss Dock database, and the molecular docking of 193 bioactive compounds was finally verified. Among them, SLC5A2, SLC5A1, LDHA, KLK1, KLF5, and GSTP1 had better binding to the protein molecules. Conclusions: Empagliflozin may regulate the targets of SLC5A2, SLC5A1, LDHA, KLK1, KLF5, and GSTP1. There are numerous ways of treating T2DM with empagliflozin, including by regulating apoptosis, cell aging, as well as the NF-κB, HIF-1HIF-1, Ras, MAPK, FoxO, P13K-Akt, and p53 pathways.

2.
Metab Syndr Relat Disord ; 17(8): 416-422, 2019 10.
Article in English | MEDLINE | ID: mdl-31355704

ABSTRACT

Background: A number of researches have reported that thyroid hormones are associated with obesity. However, the relationship of serum levels of thyroid hormones in the normal range with obesity and parameters of obesity in women of childbearing age remains controversial. The purpose of this study was to examine serum levels of thyroid hormones within the normal range in obese Chinese women of reproductive age and to investigate the relationship between concentration of thyroid hormones and indices of obesity, including body mass index (BMI), waist-to-hip ratio (WHR), insulin resistance, blood glucose, blood lipids, and blood pressure. Methods: One hundred fifty-one obese women of reproductive age and 160 nonobese women of reproductive age were enrolled in this study. Serum levels of thyroid-stimulating hormone (TSH) of all subjects were within the normal reference range (0.35-4.94 mIU/L). The serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and TSH, height, body weight, BMI, waist and hip circumferences, WHR, fasting blood glucose (FBG), fasting insulin (FI), homeostasis model assessment of insulin resistance (HOMA-IR), total triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured in all subjects. Quantile regression analysis was used to analyze the associations of serum levels of FT3, FT4, and TSH with values of BMI, WHR, FBG, FI, HOMA-IR, TG, TC, LDL-C, HDL-C, SBP, and DBP. Results: In the group of obese women, serum levels of FT4 were lower (P < 0.001) and serum levels of TSH were higher (P < 0.001) compared with nonobese controls. After adjusting for covariables, quantile regression analysis showed that serum levels of FT4 were inversely associated with BMI values between the quantile levels of 0.29 and 0.60 of BMI (i.e., BMI level of 22.49 and 28.31 kg/m2, respectively). Meanwhile, we found that serum levels of TSH positively correlated with BMI values after the quantile level of 0.51 (i.e., BMI level of 27.06 kg/m2), positively associated with TC after the quantile level of 0.6 (i.e., TC level of 4.86 mM), and positively associated with LDL-C after the quantile level of 0.39 (i.e., LDL level of 1.96 mM). No significant associations were found between serum levels of thyroid hormones and values of WHR, FBG, FI, HOMA-IR, TG, HDL-C, SBP, and DBP. Conclusions: FT4 and TSH play an important role in regulating the weight in women with normal thyroid function during their reproductive years. Women with decreased serum FT4 or increased serum TSH levels have a higher risk of developing obesity. Besides, TSH has a significant influence on metabolism of blood lipids. Women with higher serum levels of TSH have a higher risk of incidence of lipid metabolism disorders.


Subject(s)
Obesity/blood , Obesity/epidemiology , Obesity/etiology , Thyroid Function Tests/standards , Thyroid Hormones/blood , Adolescent , Adult , Age Factors , Body Mass Index , Case-Control Studies , China/epidemiology , Female , Health Status Indicators , Humans , Insulin Resistance , Lipids/blood , Middle Aged , Obesity/diagnosis , Reference Values , Reproduction/physiology , Risk Factors , Thyroid Hormones/standards , Young Adult
4.
J Int Med Res ; 42(6): 1202-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25186095

ABSTRACT

OBJECTIVES: To investigate plasma total ghrelin and obestatin levels and the ghrelin/obestatin ratio prospectively, in hypertensive obese patients. METHODS: Height, weight, and waist and hip circumferences were measured in hypertensive and normotensive obese patients and matched healthy controls; the body mass index and waist to hip ratio were calculated. Fasting glucose and insulin levels were measured and the homeostasis model assessment of insulin resistance (HOMA-IR) was determined. Fasting ghrelin and obestatin concentrations were measured by radioimmunoassay and the ghrelin/obestatin ratio was calculated. RESULTS: A total of 38 hypertensive obese patients, 40 normotensive obese patients and 38 controls were enrolled. Hypertensive obese patients had lower plasma levels of ghrelin and obestatin than normotensive obese patients or controls. In addition, normotensive obese patients had lower plasma ghrelin and obestatin levels than controls. In hypertensive obese patients, ghrelin and obestatin levels were negatively associated with systolic and diastolic blood pressure, fasting insulin and HOMA-IR. In normotensive obese patients, ghrelin, obestatin and the ghrelin/obestatin ratio were negatively associated with fasting insulin and HOMA-IR. In both patient groups, fasting obestatin and ghrelin concentrations were significantly and positively correlated with each other. CONCLUSION: Changes in the levels of ghrelin and obestatin may play a role in the pathophysiology of obesity and hypertension.


Subject(s)
Ghrelin/blood , Hypertension/blood , Insulin/blood , Obesity/blood , Blood Glucose/analysis , Body Height , Body Mass Index , Body Weight , Fasting/blood , Female , Humans , Male , Middle Aged , Waist Circumference , Waist-Hip Ratio
SELECTION OF CITATIONS
SEARCH DETAIL
...